The company says positive results from a clinical trial is spurring the move.
A health care worker prepares a vaccine in New York City in a file photograph. Michael M. Santiago/Getty Images
|Updated:
Moderna is going to ask regulators to approve its combination vaccine against COVID-19 and influenza, the company said on June 30.
The company said a phase 3 study evaluating its influenza vaccine candidate, mRNA-1010—which utilizes the same messenger ribonucleic acid (mRNA) platform as its COVID-19 vaccine—showed positive effectiveness.
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
